Читать книгу Sarcopenia - Группа авторов - Страница 80

Recently, there are ongoing discussions examining the role of functional outcomes of sarcopenia and muscle mass in the definition of sarcopenia itself. If the purpose of diagnosis of sarcopenia is to predict adverse outcomes so that interventional measures may be implemented (non‐pharmacological or pharmacological), then measures that actually predict adverse outcomes should be used. A community study of older adults with a mean age of 81.2 years showed that strength measures are better than muscle mass measures in predicting health‐related outcomes in older people [34]. Similarly, the Sarcopenia Definitions and Outcomes Project (supported by the National Institute on Aging and the Foundation for the National Institute of Health United States) analyzed pooled data from 10 prospective studies of community‐living older people in United States, Sweden, Amsterdam, and Hong Kong concluded that lean mass measured by dual energy x‐ray absorptiometry was not predictive of physical function, falls, or mortality, whereas more accurate estimation of muscle mass by isotope dilution method (D₃Cr) was predictive (unpublished data presented at the SDOC conference in Boston in November 2018). However, use of this method would be difficult in community and clinical settings. Furthermore, some measures currently proposed to be incorporated into the definition of sarcopenia such as grip strength, may actually influence outcomes not via muscle but through neurological pathways that represent brain health [35].